SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Alexion Pharmaceuticals Inc. Release: Data From Investigator-Initiated Phase 2 Study of Eculizumab (Soliris®) in Patients With Severe Relapsing Neuromyelitis Optica (NMO) Presented at the American Neurological Association Annual Meeting